Ningbo Menovo Pharmaceutical Co., Ltd.
Symbol: 603538.SS
SHH
14.58
CNYTrhová cena dnes
-165.8310
Pomer P/E
-26.5330
Pomer PEG
3.09B
MRK Cap
- 0.01%
Výnos DIV
Ningbo Menovo Pharmaceutical Co., Ltd. (603538-SS) Finančné výkazy
Súvaha
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 3108.99 | 724.7 | 1009.3 | 793.2 | |||||||||||||
balance-sheet.row.short-term-investments | 961.42 | 268.6 | 217.4 | 371.4 | |||||||||||||
balance-sheet.row.net-receivables | 1197.96 | 320.7 | 231.5 | 266.2 | |||||||||||||
balance-sheet.row.inventory | 2630.14 | 612.6 | 594.4 | 579.7 | |||||||||||||
balance-sheet.row.other-current-assets | 198.07 | 50.3 | 59.2 | 63.4 | |||||||||||||
balance-sheet.row.total-current-assets | 7254.8 | 1759.4 | 1894.4 | 1702.4 | |||||||||||||
balance-sheet.row.property-plant-equipment-net | 7582.87 | 1900.3 | 1801.9 | 1614.7 | |||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 22.7 | |||||||||||||
balance-sheet.row.intangible-assets | 802.34 | 206.2 | 172.5 | 201.7 | |||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 802.34 | 206.2 | 172.5 | 224.4 | |||||||||||||
balance-sheet.row.long-term-investments | 832.39 | 315.3 | 82.7 | -51.8 | |||||||||||||
balance-sheet.row.tax-assets | 335.17 | 42.7 | 123.1 | 33.3 | |||||||||||||
balance-sheet.row.other-non-current-assets | 942.78 | 199.6 | 344.8 | 478.5 | |||||||||||||
balance-sheet.row.total-non-current-assets | 10495.55 | 2664.1 | 2525.1 | 2299.1 | |||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.total-assets | 17750.35 | 4423.5 | 4419.5 | 4001.5 | |||||||||||||
balance-sheet.row.account-payables | 2040.98 | 553.7 | 499.3 | 389.1 | |||||||||||||
balance-sheet.row.short-term-debt | 2165.58 | 542.8 | 497 | 505 | |||||||||||||
balance-sheet.row.tax-payables | 115.34 | 25.5 | 72.1 | 34.6 | |||||||||||||
balance-sheet.row.long-term-debt-total | 3022.3 | 759.6 | 705.6 | 755.3 | |||||||||||||
Deferred Revenue Non Current | 330.02 | 81.5 | 70.6 | 48.7 | |||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 220.86 | - | - | - | |||||||||||||
balance-sheet.row.other-current-liab | 8.2 | 2 | 171 | 3.9 | |||||||||||||
balance-sheet.row.total-non-current-liabilities | 3592.57 | 859.6 | 884 | 876.2 | |||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.capital-lease-obligations | 102.15 | 15.7 | 30.3 | 28 | |||||||||||||
balance-sheet.row.total-liab | 8956.27 | 2237.8 | 2246.2 | 2023 | |||||||||||||
balance-sheet.row.preferred-stock | 72.59 | 36.3 | 0 | 0 | |||||||||||||
balance-sheet.row.common-stock | 853.57 | 213.4 | 213.4 | 151.3 | |||||||||||||
balance-sheet.row.retained-earnings | 4918.84 | 1210.6 | 1234.3 | 937.4 | |||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 986.88 | 75.6 | 101.4 | 77.6 | |||||||||||||
balance-sheet.row.other-total-stockholders-equity | 1595.49 | 560.4 | 535.9 | 585.2 | |||||||||||||
balance-sheet.row.total-stockholders-equity | 8427.36 | 2096.3 | 2085 | 1751.5 | |||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 17750.35 | 4423.5 | 4419.5 | 4001.5 | |||||||||||||
balance-sheet.row.minority-interest | 366.72 | 89.4 | 88.3 | 227 | |||||||||||||
balance-sheet.row.total-equity | 8794.08 | 2185.7 | 2173.2 | 1978.5 | |||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 17750.35 | - | - | - | |||||||||||||
Total Investments | 1259.87 | 315.3 | 300.1 | 319.6 | |||||||||||||
balance-sheet.row.total-debt | 5187.88 | 1302.5 | 1202.6 | 1260.4 | |||||||||||||
balance-sheet.row.net-debt | 3040.31 | 846.4 | 410.7 | 838.6 |
Výkaz peňažných tokov
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -17.82 | 367.6 | 158.1 | 173.1 | ||||||||||||
cash-flows.row.depreciation-and-amortization | 90.3 | 101.8 | 98.9 | 85 | ||||||||||||
cash-flows.row.deferred-income-tax | -13.64 | -40.2 | -21 | 18.4 | ||||||||||||
cash-flows.row.stock-based-compensation | 11.27 | 24.7 | 5.3 | 10.9 | ||||||||||||
cash-flows.row.change-in-working-capital | -124.06 | -85.4 | -62.2 | -2.8 | ||||||||||||
cash-flows.row.account-receivables | -98.84 | -213.6 | -50.9 | -28.2 | ||||||||||||
cash-flows.row.inventory | -49.56 | -183 | -124.7 | -83 | ||||||||||||
cash-flows.row.account-payables | 0 | 351.4 | 134.4 | 63.3 | ||||||||||||
cash-flows.row.other-working-capital | 24.33 | -40.2 | -21 | 45.1 | ||||||||||||
cash-flows.row.other-non-cash-items | 36.58 | -91.4 | 41.5 | -32.9 | ||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -28.65 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -142.43 | -571.6 | -529.9 | -311.7 | ||||||||||||
cash-flows.row.acquisitions-net | 0.3 | 487.9 | -47.1 | 0.5 | ||||||||||||
cash-flows.row.purchases-of-investments | -994.74 | -713.9 | -1640.5 | -865 | ||||||||||||
cash-flows.row.sales-maturities-of-investments | 853.67 | 902.5 | 1562.2 | 693.5 | ||||||||||||
cash-flows.row.other-investing-activites | -116.67 | -54.6 | 52 | 3.8 | ||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -247.84 | 50.3 | -603.3 | -479 | ||||||||||||
cash-flows.row.debt-repayment | -399.52 | -749.5 | -788.1 | -802.5 | ||||||||||||
cash-flows.row.common-stock-issued | 0 | 0.1 | 0.2 | 0.5 | ||||||||||||
cash-flows.row.common-stock-repurchased | 0 | -0.1 | -0.2 | -0.5 | ||||||||||||
cash-flows.row.dividends-paid | -60.49 | -50 | -13.8 | -41 | ||||||||||||
cash-flows.row.other-financing-activites | 446.21 | 621.1 | 1385.1 | 981.9 | ||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 60.68 | -178.5 | 583.1 | 138.4 | ||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | -22.05 | 14.6 | -2.3 | -2 | ||||||||||||
cash-flows.row.net-change-in-cash | -237.86 | 163.4 | 198.2 | -91 | ||||||||||||
cash-flows.row.cash-at-end-of-period | 1234.49 | 537 | 373.6 | 174.5 | ||||||||||||
cash-flows.row.cash-at-beginning-of-period | 1472.34 | 373.6 | 175.4 | 265.5 | ||||||||||||
cash-flows.row.operating-cash-flow | -28.65 | 277 | 220.6 | 251.6 | ||||||||||||
cash-flows.row.capital-expenditure | -142.43 | -571.6 | -529.9 | -311.7 | ||||||||||||
cash-flows.row.free-cash-flow | -171.08 | -294.7 | -309.3 | -60.1 |
Riadok výkazu ziskov a strát
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 1232.95 | 1216.5 | 1457 | 1258.1 | |||||||||||||
income-statement-row.row.cost-of-revenue | 839.39 | 840.9 | 872.8 | 788.9 | |||||||||||||
income-statement-row.row.gross-profit | 393.56 | 375.6 | 584.2 | 469.2 | |||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||
income-statement-row.row.research-development | 99.54 | - | - | - | |||||||||||||
income-statement-row.row.selling-general-administrative | 57.01 | - | - | - | |||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 52.13 | - | - | - | |||||||||||||
income-statement-row.row.other-expenses | -11.95 | -10.8 | 116.4 | 110.8 | |||||||||||||
income-statement-row.row.operating-expenses | 305.9 | 291.2 | 341.4 | 281 | |||||||||||||
income-statement-row.row.cost-and-expenses | 1145.29 | 1132.1 | 1214.2 | 1069.9 | |||||||||||||
income-statement-row.row.interest-income | 6.12 | 5.5 | 5.7 | 2.2 | |||||||||||||
income-statement-row.row.interest-expense | 30.96 | 29.1 | 27.4 | 27.2 | |||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 52.13 | - | - | - | |||||||||||||
income-statement-row.row.total-other-income-expensenet | -77.38 | -76.4 | -21.2 | -7.6 | |||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||
income-statement-row.row.other-operating-expenses | -11.95 | -10.8 | 116.4 | 110.8 | |||||||||||||
income-statement-row.row.total-operating-expenses | -77.38 | -76.4 | -21.2 | -7.6 | |||||||||||||
income-statement-row.row.interest-expense | 30.96 | 29.1 | 27.4 | 27.2 | |||||||||||||
income-statement-row.row.depreciation-and-amortization | 125.92 | 118.5 | 128.3 | 124.1 | |||||||||||||
income-statement-row.row.ebitda-caps | 59.17 | - | - | - | |||||||||||||
income-statement-row.row.operating-income | -15.63 | 18.7 | 405.3 | 187.9 | |||||||||||||
income-statement-row.row.income-before-tax | -27.57 | 8 | 384.2 | 180.3 | |||||||||||||
income-statement-row.row.income-tax-expense | -13.31 | -8.2 | 16.5 | 22.2 | |||||||||||||
income-statement-row.row.net-income | -17.82 | 11.6 | 338.9 | 142.5 |
Často kladené otázky
Čo je Ningbo Menovo Pharmaceutical Co., Ltd. (603538.SS) celkové aktíva?
Ningbo Menovo Pharmaceutical Co., Ltd. (603538.SS) celkové aktíva sú 4423515920.000.
Aký je ročný obrat podniku?
Ročné príjmy sú 550731997.000.
Aké je ziskové rozpätie podniku?
Zisková marža firmy je 0.319.
Aký je voľný peňažný tok podniku?
Voľný peňažný tok je -0.853.
Aká je čistá zisková marža podniku?
Čistá zisková marža je -0.014.
Aké sú celkové výnosy podniku?
Celkové príjmy sú -0.013.
Aká je Ningbo Menovo Pharmaceutical Co., Ltd. (603538.SS) čistý zisk (čistý príjem)?
Čistý zisk (čistý príjem) je 11585592.000.
Aký je celkový dlh firmy?
Celkový dlh je 1302458461.000.
Aké je číslo prevádzkových nákladov?
Prevádzkové výdavky sú 291175048.000.
Aký je údaj o hotovosti spoločnosti?
Peňažné prostriedky podniku sú 351891745.000.